Federal health advisers said Wednesday that a highly-anticipated cholesterol-lowering drug from Amgen Inc. should be approved for patients with dangerously high levels of the artery-clogging substance.
Patients with chronic heart failure, a deadly disease that worsens as the heart pumps less blood through the body, are getting a much-needed new option.
Amgen Inc., the Thousand Oaks, Calif., biotech giant, said Sunday a new study has found its cancer drug Kyprolis is far more effective in treatment of relapsed multiple myeloma than its chief rival.
Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" ...
Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...
Amgen Inc.'s fourth-quarter profit jumped 30 percent due to higher sales for nearly all its drugs, an acquisition and a tax benefit.
(HealthDay)—High low-density lipoprotein (LDL) cholesterol remains common among U.S. adults, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.
(HealthDay)—For patients with early breast cancer, a response-guided neoadjuvant chemotherapy approach seems beneficial, according to a study published online Sept. 3 in the Journal of Clinical Oncology.
AstraZeneca said on Tuesday that it has agreed to buy US-based cancer drugs company Amplimmune, as the Anglo-Swedish pharmaceuticals group seeks to bolster its flagging pipeline of new products.
Biotech drugmaker Amgen is reportedly close to buying cancer drug maker Onyx Pharmaceuticals for about $10.5 billion.
Amgen Inc. said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines.
(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.
Dry eye disease (DED) is a common condition that causes discomfort, visual disturbance and potentially damaging ocular surface inflammation that greatly impacts a person's quality of life. An estimated nine million people ...
(HealthDay)—A system of Web-based consultations (telenephrology) may reduce the number of specialty referrals for patients with chronic kidney disease, according to a study published in the March/April ...